After yet another FDA delay regarding Vascepa's NCE status, Amarin (AMRN 0.79%) investors may have something to celebrate today: The company stayed true to its reported timeline and has launched its lipid-lowering drug. While this launch does signify progress at the company, it will go head to head with Lovaza, a drug marketed by pharma giant GlaxoSmithKline (GSK +2.89%). In this video, our health care analyst Max Macaluso discusses whether this is news investors should welcome -- and what they should be wary of.
The Day Amarin Investors Have Waited For
By Max Macaluso – Jan 24, 2013 at 4:05PM
NASDAQ: AMRN
Amarin Plc
Market Cap
$407M
Today's Change
(-0.79%) $0.15
Current Price
$19.46
Price as of October 23, 2025 at 4:00 PM ET
It's finally here... but it's not NCE.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo